Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Starpharma and the Monash Institute of Pharmaceutical Sciences (MIPS) have received fund from Australian Research Council for advancing a new drug delivery method that may benefit thousands of patients with particular types of cancer, HIV and lymphatic conditions world-wide.
Subscribe to our email newsletter
Minister for Innovation, Industry, Science and Research of Australia has awarded $420,000 fund to Starpharma and MIPS as part of the ARC’s Linkage Projects scheme aimed at encouraging Australian institutions to undertake innovative and research projects in collaboration with industry and other partners.
Chris Porter, lead researcher and associate dean of research at MIPS, said: “The
technology has particular implications for the treatment of diseases which are spread via the lymphatics and lymph nodes.
“Our work so far suggests that careful design of the size and surface characteristics of certain dendrimers provides an opportunity to boost delivery to the lymphatic system, signalling the potential to significantly improve patient treatment This Linkage grant provides an excellent opportunity to explore these issues in detail and to advance the development of targeted therapeutics.”
Jackie Fairley, CEO of Starpharma, said: “This funding will assist in advancing our collaboration with researchers from Monash University over the next three years, to further understand the full potential of Starpharma’s proprietary dendrimers in improving drug delivery.
“This research has the potential to significantly improve the treatment of diseases, including metastatic cancer, lymphoma, HIV and metastitial tuberculosis.”